JP2021527407A - 全般的アミロイド相互作用モチーフ(gaim) - Google Patents
全般的アミロイド相互作用モチーフ(gaim) Download PDFInfo
- Publication number
- JP2021527407A JP2021527407A JP2020569166A JP2020569166A JP2021527407A JP 2021527407 A JP2021527407 A JP 2021527407A JP 2020569166 A JP2020569166 A JP 2020569166A JP 2020569166 A JP2020569166 A JP 2020569166A JP 2021527407 A JP2021527407 A JP 2021527407A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gaim
- amyloid
- polypeptide
- amyloidosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003993 interaction Effects 0.000 title abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 87
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 84
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 77
- 201000010099 disease Diseases 0.000 claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000013598 vector Substances 0.000 claims abstract description 30
- 230000006933 amyloid-beta aggregation Effects 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 215
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 207
- 229920001184 polypeptide Polymers 0.000 claims description 200
- 235000001014 amino acid Nutrition 0.000 claims description 191
- 150000001413 amino acids Chemical group 0.000 claims description 186
- 238000006467 substitution reaction Methods 0.000 claims description 105
- 210000004027 cell Anatomy 0.000 claims description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 206010002022 amyloidosis Diseases 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 59
- 235000018102 proteins Nutrition 0.000 claims description 50
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 37
- 235000018417 cysteine Nutrition 0.000 claims description 37
- 208000024827 Alzheimer disease Diseases 0.000 claims description 25
- 108091000054 Prion Proteins 0.000 claims description 25
- 206010012289 Dementia Diseases 0.000 claims description 24
- 102000029797 Prion Human genes 0.000 claims description 21
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 19
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 17
- 239000004473 Threonine Substances 0.000 claims description 17
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 15
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 230000003941 amyloidogenesis Effects 0.000 claims description 11
- 230000002490 cerebral effect Effects 0.000 claims description 11
- 231100000331 toxic Toxicity 0.000 claims description 11
- 230000002588 toxic effect Effects 0.000 claims description 11
- 206010016202 Familial Amyloidosis Diseases 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102200068707 rs281865211 Human genes 0.000 claims description 9
- 208000014644 Brain disease Diseases 0.000 claims description 8
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 8
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 8
- 206010034010 Parkinsonism Diseases 0.000 claims description 8
- 208000034799 Tauopathies Diseases 0.000 claims description 8
- 201000006061 fatal familial insomnia Diseases 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims description 8
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 7
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 7
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 7
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 210000004102 animal cell Anatomy 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 230000007850 degeneration Effects 0.000 claims description 7
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 208000005264 motor neuron disease Diseases 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 claims description 7
- 230000000750 progressive effect Effects 0.000 claims description 7
- 208000032274 Encephalopathy Diseases 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 6
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 6
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 6
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 6
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000004153 islets of langerhan Anatomy 0.000 claims description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 6
- 102000014461 Ataxins Human genes 0.000 claims description 5
- 108010078286 Ataxins Proteins 0.000 claims description 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 5
- 102000004878 Gelsolin Human genes 0.000 claims description 5
- 108090001064 Gelsolin Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 5
- 230000001746 atrial effect Effects 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 210000003478 temporal lobe Anatomy 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 102000012192 Cystatin C Human genes 0.000 claims description 4
- 108010061642 Cystatin C Proteins 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims description 4
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 108010048233 Procalcitonin Proteins 0.000 claims description 4
- 102100024819 Prolactin Human genes 0.000 claims description 4
- 108010057464 Prolactin Proteins 0.000 claims description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 208000017004 dementia pugilistica Diseases 0.000 claims description 4
- 210000003298 dental enamel Anatomy 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000001882 diuretic effect Effects 0.000 claims description 4
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 4
- 229940097325 prolactin Drugs 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims description 4
- 208000023769 AA amyloidosis Diseases 0.000 claims description 3
- 208000023697 ABri amyloidosis Diseases 0.000 claims description 3
- 208000017227 ADan amyloidosis Diseases 0.000 claims description 3
- 208000023761 AL amyloidosis Diseases 0.000 claims description 3
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims description 3
- 102100032187 Androgen receptor Human genes 0.000 claims description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 3
- 102000007372 Ataxin-1 Human genes 0.000 claims description 3
- 108010032963 Ataxin-1 Proteins 0.000 claims description 3
- 102000004321 Atrophin-1 Human genes 0.000 claims description 3
- 108090000806 Atrophin-1 Proteins 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 3
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 3
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 3
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims description 3
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 3
- 108010063045 Lactoferrin Proteins 0.000 claims description 3
- 208000024571 Pick disease Diseases 0.000 claims description 3
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 claims description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 3
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 3
- 102000006467 TATA-Box Binding Protein Human genes 0.000 claims description 3
- 108010044281 TATA-Box Binding Protein Proteins 0.000 claims description 3
- 108010080146 androgen receptors Proteins 0.000 claims description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 3
- 206010011005 corneal dystrophy Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 208000017105 hereditary amyloidosis Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
- 229940078795 lactoferrin Drugs 0.000 claims description 3
- 235000021242 lactoferrin Nutrition 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims description 3
- 230000002739 subcortical effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000002123 temporal effect Effects 0.000 claims description 3
- 208000018282 ACys amyloidosis Diseases 0.000 claims description 2
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 2
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims description 2
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims description 2
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims description 2
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims description 2
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims description 2
- 108010076876 Keratins Proteins 0.000 claims description 2
- 102000011782 Keratins Human genes 0.000 claims description 2
- 101800004937 Protein C Proteins 0.000 claims description 2
- 101800001700 Saposin-D Proteins 0.000 claims description 2
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 claims description 2
- 102000013069 gamma-Crystallins Human genes 0.000 claims description 2
- 108010079934 gamma-Crystallins Proteins 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 229960000856 protein c Drugs 0.000 claims description 2
- 102100034452 Alternative prion protein Human genes 0.000 claims 4
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 102000010445 Lactoferrin Human genes 0.000 claims 1
- 102400000827 Saposin-D Human genes 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 99
- 102000037865 fusion proteins Human genes 0.000 abstract description 88
- 108020001507 fusion proteins Proteins 0.000 abstract description 88
- 238000007634 remodeling Methods 0.000 abstract description 45
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract description 32
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract description 32
- 230000001965 increasing effect Effects 0.000 abstract description 16
- 241001515965 unidentified phage Species 0.000 abstract description 15
- 101710192393 Attachment protein G3P Proteins 0.000 abstract description 2
- 101710179596 Gene 3 protein Proteins 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 177
- 230000004927 fusion Effects 0.000 description 109
- 125000003275 alpha amino acid group Chemical group 0.000 description 69
- 239000000835 fiber Substances 0.000 description 68
- 239000000203 mixture Substances 0.000 description 48
- 102000013498 tau Proteins Human genes 0.000 description 44
- 108010026424 tau Proteins Proteins 0.000 description 44
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 33
- 210000001744 T-lymphocyte Anatomy 0.000 description 30
- 230000035772 mutation Effects 0.000 description 30
- 238000009472 formulation Methods 0.000 description 25
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 23
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 23
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 22
- 229960000789 guanidine hydrochloride Drugs 0.000 description 22
- 239000000539 dimer Substances 0.000 description 21
- 238000001802 infusion Methods 0.000 description 20
- 230000000087 stabilizing effect Effects 0.000 description 20
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 17
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 239000000178 monomer Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 108091007786 fibrillar β-amyloid peptide (1-42) Proteins 0.000 description 12
- 239000004202 carbamide Substances 0.000 description 11
- 229920000136 polysorbate Polymers 0.000 description 11
- 208000037259 Amyloid Plaque Diseases 0.000 description 10
- 241001524679 Escherichia virus M13 Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000007704 transition Effects 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000012216 imaging agent Substances 0.000 description 9
- 102000001049 Amyloid Human genes 0.000 description 8
- 108010094108 Amyloid Proteins 0.000 description 8
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 108010071690 Prealbumin Proteins 0.000 description 8
- 102000009190 Transthyretin Human genes 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 102220497670 Leukotriene B4 receptor 1_N38A_mutation Human genes 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 102000003802 alpha-Synuclein Human genes 0.000 description 7
- 108090000185 alpha-Synuclein Proteins 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 6
- 102100025818 Major prion protein Human genes 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000007153 proteostasis deficiencies Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000350158 Prioria balsamifera Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000007913 intrathecal administration Methods 0.000 description 4
- 238000007914 intraventricular administration Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- -1 aromatic amino acids Chemical class 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000022811 deglycosylation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 102200158871 rs33955330 Human genes 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102100032241 Lactotransferrin Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000011542 SDS running buffer Substances 0.000 description 2
- 208000018642 Semantic dementia Diseases 0.000 description 2
- 241000256248 Spodoptera Species 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000007387 gliosis Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- AIDBEARHLBRLMO-UHFFFAOYSA-M sodium;dodecyl sulfate;2-morpholin-4-ylethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O AIDBEARHLBRLMO-UHFFFAOYSA-M 0.000 description 2
- 238000007921 solubility assay Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 101150091111 ACAN gene Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 230000007134 Aβ oligomerisation Effects 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 201000004176 Gelatinous drop-like corneal dystrophy Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 1
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000209501 Spirodela Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 101000707286 Xenopus laevis Protein Shroom1 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010001122 alpha(2)-microglobulin Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229930002869 chlorophyll b Natural products 0.000 description 1
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000012432 intermediate storage Methods 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000003775 lattice corneal dystrophy Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102220094195 rs876660417 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
これらの進歩にもかかわらず、より安定、強力、および特異的であり、ならびに完全またはほぼ完全に脱免疫されたg3pポリペプチドが当技術分野でなおも必要である。
配列番号1=AETVESCLAKPHTENSFTNVWKDDKTLDRYAN
定義
G3pの全般的アミロイド相互作用モチーフ(GAIM)およびそのGAIM−Ig融合体
ポリペプチドの調製
医薬組成物
治療的使用
診断
組換え技術
タウK18P301L発現、精製および線維集合
P213L変異を有するタウ−441(2N4R)の残基244〜372に対応するヒトタウK18P301L断片を、タウ−MTBRについて記載されたとおりに発現させ、精製した(Krishnan et al. (2014) J Mol Biol, 426:2500-19)。2mM DTTを含有する0.1M酢酸ナトリウムpH7.0バッファー中の40μMのタウK18P301L単量体に、40μMの低分子量ヘパリン(Fisher Scientific)を添加することおよび37℃で3日間インキュベートすることによって、タウ−K18P301L線維を集合させた。線維形成は、チオフラビンT(ThT)によって確認した。
(実施例2)
Aβ線維集合
(実施例3)
GAIM−Ig融合タンパク質の作製
(実施例4)
GAIM二量体の作製
(実施例5)
SYPRO(登録商標)Orange結合アッセイによってモニターされたGAIMの熱的アンフォールディング
(実施例6)
GAIMは、IgG融合二量体でその天然コンフォメーション安定性を保持する
(実施例7)
GAIM−Ig融合体は、Aβおよびタウ線維と結合する
(実施例8)
安定化されたGAIM−Ig融合タンパク質にわたるオープン安定化GAIM−Ig融合タンパク質の優れた結合
(実施例9)
GAIM−Ig融合体は、多様な形態を有する複数のアミロイドを標的とする
(実施例10)
GAIM−Ig融合体は、アミロイドタンパク質と特異的に結合する
(実施例11)
オープン安定化GAIM−Ig融合体は、Aβ線維の増強されたリモデリングを示す
(実施例12)
オープン安定化GAIM−Ig融合体は、タウK18P301L線維の増強されたリモデリングを示す
(実施例13)
オープン安定化GAIM−Ig融合体は、アミロイド線維に線維状構築物を喪失させる
(実施例14)
オープン安定化GAIM−Ig融合体は、アミロイド凝集の阻害の増加を示す
特定の実施形態では、例えば以下の項目が提供される。
(項目1)
配列番号16の開始アミノ酸配列のバリアントを含むポリペプチドであって、前記バリアントが:
a)任意のアミノ酸でのT50の置換およびH55T;
b)N137G;
c)N142A;
d)R143VおよびQ144N;または
R143V、Q144N、およびA146V;または
R143V、Q144N、およびA146T;または
R143V、Q144N、およびA146K;ならびに
e)Q156V、G157N、ΔT158、ΔD159、ΔP160、およびV161G;または
Q156Y、G157N、ΔT158、ΔD159、ΔP160、およびV161G;または
G157N、ΔT158、ΔD159、ΔP160、およびV161G;または
ΔT158、ΔD159、ΔP160、およびV161G
から選択されるアミノ酸変化の1つまたは複数のセットによって配列番号16とは異なり、前記バリアントが必要に応じて:
f)ΔM1;または
ΔM1およびΔA2;ならびに
g)システイン以外の任意のアミノ酸でのN38の置換;または
システイン以外の任意のアミノ酸でのN38の置換、およびシステイン以外の任意のアミノ酸でのG40の置換;または
システイン、トレオニン、もしくはセリン以外の任意のアミノ酸でのG40の置換
から選択されるアミノ酸変化の1つまたは複数のセットによって配列番号16とはさらに異なるポリペプチド。
(項目2)
前記T50置換が、T50G、T50H、T50K、およびT50Rからなる群から選択される、項目1に記載のポリペプチド。
(項目3)
前記T50置換がT50Hである、項目2に記載のポリペプチド。
(項目4)
前記バリアントが、少なくともΔM1およびΔA2によって配列番号16とは異なる、項目1に記載のポリペプチド。
(項目5)
前記バリアントが、少なくともN137Gおよび/またはN142Aによって配列番号16とは異なる、項目1から4のいずれか一項に記載のポリペプチド。
(項目6)
前記バリアントが:
a)任意のアミノ酸でのT50の置換、およびH55T;ならびに
b)R143VおよびQ144N;または
R143V、Q144N、およびA146V;または
R143V、Q144N、およびA146T;または
R143V、Q144N、およびA146K
から選択されるアミノ酸変化の1つまたは複数のセットによって配列番号16とはさらに異なる、項目4に記載のポリペプチド。
(項目7)
前記T50置換が、T50G、T50H、T50K、およびT50Rからなる群から選択される、項目6に記載のポリペプチド。
(項目8)
前記T50置換がT50Hである、項目7に記載のポリペプチド。
(項目9)
配列番号16の前記バリアントが、配列番号19、配列番号20、配列番号21、配列番号22、配列番号23、配列番号24、配列番号25、および配列番号26からなる群から選択される、項目1に記載のポリペプチド。
(項目10)
免疫グロブリン定常領域をさらに含む、項目1から9のいずれか一項に記載のポリペプチド。
(項目11)
前記免疫グロブリン定常領域配列が、ヒトIgGのFc部分である、項目10に記載のポリペプチド。
(項目12)
項目1から9のいずれか一項に記載のポリペプチドおよびヒトIgGのFc部分から本質的になる、項目11に記載のポリペプチド。
(項目13)
前記ヒトIgGがヒトIgG1である、項目12に記載のポリペプチド。
(項目14)
a)配列番号29;
b)配列番号30;
c)配列番号31;
d)配列番号32;
e)配列番号33;
f)配列番号34;
g)配列番号35;および
h)配列番号36;
から選択されるアミノ酸配列から本質的になるポリペプチドであって、
前記バリアントが、必要に応じて:
i)ΔM1;または
ΔM1およびΔA2;ならびに
j)ΔK485
から選択されるアミノ酸変化の1つまたは複数のセットを有するポリペプチド。
(項目15)
項目1から14のいずれか一項に記載のポリペプチドおよび薬学的に許容される担体を含む医薬組成物。
(項目16)
アミロイドを低減させる、アミロイド形成を阻害する、アミロイド凝集を阻害する、または毒性オリゴマーを除去および/もしくはその形成を防止することを必要とする対象においてアミロイドを低減させる、アミロイド形成を阻害する、アミロイド凝集を阻害する、または毒性オリゴマーを除去および/もしくはその形成を防止する方法であって、前記対象に項目1から14のいずれか一項に記載のポリペプチドまたは項目15に記載の医薬組成物を投与するステップを含む方法。
(項目17)
前記アミロイドまたはオリゴマーが、アンドロゲン受容体;アポリポタンパク質AI;アポリポタンパク質AII;アポリポタンパク質AIV;アポ血清アミロイドA;Aβ;ABri;ADan;アトロフィン−1;心房性ナトリウム利尿因子;アタキシン;カルシトニン;γ−クリスタリン;シスタチンC;フィブリノゲン;ゲルソリン;ハンチンチン;インスリン;膵島アミロイドポリペプチド;免疫グロブリンカッパ軽鎖;免疫グロブリンラムダ軽鎖;ケラトエピセリン;ケラチン;ラクタヘドリン;ラクトフェリン;リゾチーム;肺サーファクタントタンパク質C;メディン;歯原性エナメル芽細胞関連タンパク質;プリオンタンパク質;プロカルシトニン;プロラクチン;セメノゲリンI;血清アミロイドA;スーパーオキシドジスムターゼI;β2−ミクログロブリン;TATAボックス結合タンパク質;タウ;トランスサイレチン;およびα−シヌクレインから選択されるタンパク質を含む、項目16に記載の方法。
(項目18)
アルツハイマー病;早期発症型アルツハイマー病;後期発症型アルツハイマー病;発症前アルツハイマー病;ALアミロイドーシス;筋萎縮性側索硬化症(ALS);筋萎縮性側索硬化症/パーキンソニズム認知症複合;嗜銀顆粒性認知症;大動脈中膜アミロイドーシス;ApoAIアミロイドーシス;ApoAIIアミロイドーシス;ApoAIVアミロイドーシス;心房アミロイドーシス;イギリス型/デンマーク型認知症;白内障;大脳皮質基底核変性症;逆まつげに関連する角膜アミロイドーシス;シスタチンCプラーク関連疾患;シスタチンCプラーク関連冠動脈疾患;シスタチンCプラーク関連腎疾患;皮膚苔癬アミロイドーシス;ボクサー認知症;歯状核赤核−淡蒼球ルイ体萎縮症;石灰化を伴うびまん性神経原線維変化病;レヴィー小体認知症;ダウン症候群;家族性アミロイド心筋症(FAC);家族性アミロイドポリニューロパチー(FAP);家族性イギリス型認知症;家族性デンマーク型認知症;家族性脳症;家族性地中海熱;フィブリノゲンアミロイドーシス;フィンランド型遺伝性アミロイドーシス;パーキンソニズムを伴う前頭側頭型認知症;前頭側頭葉変性症(FTLD);前頭側頭葉認知症;ハレルフォルデン‐スパッツ病;血液透析関連性アミロイドーシス;遺伝性脳アミロイド血管症;アミロイドーシスを伴う遺伝性脳出血;遺伝性格子状角膜ジストロフィー;ハンチントン病;アイスランド型遺伝性脳アミロイド血管症;封入体筋炎;注射部位限局性アミロイドーシス;膵島アミロイドポリペプチドアミロイドーシス;リゾチームアミロイドーシス;多発性骨髄腫;筋強直性ジストロフィー;ニーマン・ピック病C型;神経原線維変化を伴う非グアム型運動ニューロン疾患;パーキンソン病;末梢性アミロイドーシス;ピック病;下垂体プロラクチノーマ;脳炎後パーキンソニズム;プリオンタンパク質脳アミロイド血管症;プリオン媒介性疾患;クールー;クロイツフェルト・ヤコブ病(CJD);ゲルストマン・ストロイスラー・シャインカー病(GSS);致死性家族性不眠症(FFI);スクレイピー;海綿状脳症;肺胞タンパク症;進行性皮質下グリオ−シス;進行性核上麻痺;老年性全身性アミロイドーシス;血清AAアミロイドーシス;球脊髄性筋萎縮症;脊髄小脳失調症(SCA1、SCA3、SCA6、またはSCA7);亜急性硬化性全脳炎;全身性アミロイドーシス;家族性アミロイドーシス;野生型アミロイドーシス;神経原線維変化優位型認知症;およびタウオパチーから選択される疾患を処置する方法。
(項目19)
前記疾患が、パーキンソン病、アルツハイマー病、およびハンチントン病から選択される、項目18に記載の方法。
(項目20)
前記疾患がアルツハイマー病である、項目19に記載の方法。
(項目21)
前記疾患が、クロイツフェルト・ヤコブ病、クールー、致死性家族性不眠症、およびゲルストマン・ストロイスラー・シャインカー症候群から選択されるプリオン媒介性疾患である、項目18に記載の方法。
(項目22)
項目1から14のいずれか一項に記載のポリペプチドをコードする核酸を含むオリゴヌクレオチド。
(項目23)
前記ポリペプチドをコードする前記核酸が、配列番号37、配列番号38、配列番号39、配列番号40、配列番号41、配列番号42、配列番号43、および配列番号44から選択される配列を含む、項目22に記載のオリゴヌクレオチド。
(項目24)
前記ポリペプチドをコードする前記核酸が、配列番号45、配列番号46、配列番号47、配列番号48、配列番号49、配列番号50、配列番号51、および配列番号52から選択される配列からなる、項目22に記載のオリゴヌクレオチド。
(項目25)
項目22から24のいずれか一項に記載の核酸を含むベクター。
(項目26)
項目25に記載のベクターを含む宿主細胞。
(項目27)
昆虫細胞、真菌細胞、植物細胞、細菌細胞、哺乳動物細胞、およびトランスジェニック動物細胞からなる群から選択される、項目26に記載の宿主細胞。
(項目28)
HEK293細胞、HEK293由来細胞、CHO細胞、CHO由来細胞、HeLa細胞、およびCOS細胞からなる群から選択される、項目27に記載の宿主細胞。
(項目29)
アミロイドに結合するタンパク質を作製する方法であって、項目25に記載のベクター中の核酸によってコードされるタンパク質を発現させるステップ、および前記発現されたタンパク質を単離するステップを含む方法。
(項目30)
項目25に記載のベクター中の核酸によってコードされるタンパク質を発現させ、前記発現されたタンパク質を単離することによって産出される、アミロイドに結合するタンパク質。
(項目31)
項目26〜28のいずれか一項に記載の宿主細胞を培養することによって発現される、項目30に記載のタンパク質。
Claims (31)
- 配列番号16の開始アミノ酸配列のバリアントを含むポリペプチドであって、前記バリアントが:
a)任意のアミノ酸でのT50の置換およびH55T;
b)N137G;
c)N142A;
d)R143VおよびQ144N;または
R143V、Q144N、およびA146V;または
R143V、Q144N、およびA146T;または
R143V、Q144N、およびA146K;ならびに
e)Q156V、G157N、ΔT158、ΔD159、ΔP160、およびV161G;または
Q156Y、G157N、ΔT158、ΔD159、ΔP160、およびV161G;または
G157N、ΔT158、ΔD159、ΔP160、およびV161G;または
ΔT158、ΔD159、ΔP160、およびV161G
から選択されるアミノ酸変化の1つまたは複数のセットによって配列番号16とは異なり、前記バリアントが必要に応じて:
f)ΔM1;または
ΔM1およびΔA2;ならびに
g)システイン以外の任意のアミノ酸でのN38の置換;または
システイン以外の任意のアミノ酸でのN38の置換、およびシステイン以外の任意のアミノ酸でのG40の置換;または
システイン、トレオニン、もしくはセリン以外の任意のアミノ酸でのG40の置換
から選択されるアミノ酸変化の1つまたは複数のセットによって配列番号16とはさらに異なるポリペプチド。 - 前記T50置換が、T50G、T50H、T50K、およびT50Rからなる群から選択される、請求項1に記載のポリペプチド。
- 前記T50置換がT50Hである、請求項2に記載のポリペプチド。
- 前記バリアントが、少なくともΔM1およびΔA2によって配列番号16とは異なる、請求項1に記載のポリペプチド。
- 前記バリアントが、少なくともN137Gおよび/またはN142Aによって配列番号16とは異なる、請求項1から4のいずれか一項に記載のポリペプチド。
- 前記バリアントが:
a)任意のアミノ酸でのT50の置換、およびH55T;ならびに
b)R143VおよびQ144N;または
R143V、Q144N、およびA146V;または
R143V、Q144N、およびA146T;または
R143V、Q144N、およびA146K
から選択されるアミノ酸変化の1つまたは複数のセットによって配列番号16とはさらに異なる、請求項4に記載のポリペプチド。 - 前記T50置換が、T50G、T50H、T50K、およびT50Rからなる群から選択される、請求項6に記載のポリペプチド。
- 前記T50置換がT50Hである、請求項7に記載のポリペプチド。
- 配列番号16の前記バリアントが、配列番号19、配列番号20、配列番号21、配列番号22、配列番号23、配列番号24、配列番号25、および配列番号26からなる群から選択される、請求項1に記載のポリペプチド。
- 免疫グロブリン定常領域をさらに含む、請求項1から9のいずれか一項に記載のポリペプチド。
- 前記免疫グロブリン定常領域配列が、ヒトIgGのFc部分である、請求項10に記載のポリペプチド。
- 請求項1から9のいずれか一項に記載のポリペプチドおよびヒトIgGのFc部分から本質的になる、請求項11に記載のポリペプチド。
- 前記ヒトIgGがヒトIgG1である、請求項12に記載のポリペプチド。
- a)配列番号29;
b)配列番号30;
c)配列番号31;
d)配列番号32;
e)配列番号33;
f)配列番号34;
g)配列番号35;および
h)配列番号36;
から選択されるアミノ酸配列から本質的になるポリペプチドであって、
前記バリアントが、必要に応じて:
i)ΔM1;または
ΔM1およびΔA2;ならびに
j)ΔK485
から選択されるアミノ酸変化の1つまたは複数のセットを有するポリペプチド。 - 請求項1から14のいずれか一項に記載のポリペプチドおよび薬学的に許容される担体を含む医薬組成物。
- アミロイドを低減させる、アミロイド形成を阻害する、アミロイド凝集を阻害する、または毒性オリゴマーを除去および/もしくはその形成を防止することを必要とする対象においてアミロイドを低減させる、アミロイド形成を阻害する、アミロイド凝集を阻害する、または毒性オリゴマーを除去および/もしくはその形成を防止する方法であって、前記対象に請求項1から14のいずれか一項に記載のポリペプチドまたは請求項15に記載の医薬組成物を投与するステップを含む方法。
- 前記アミロイドまたはオリゴマーが、アンドロゲン受容体;アポリポタンパク質AI;アポリポタンパク質AII;アポリポタンパク質AIV;アポ血清アミロイドA;Aβ;ABri;ADan;アトロフィン−1;心房性ナトリウム利尿因子;アタキシン;カルシトニン;γ−クリスタリン;シスタチンC;フィブリノゲン;ゲルソリン;ハンチンチン;インスリン;膵島アミロイドポリペプチド;免疫グロブリンカッパ軽鎖;免疫グロブリンラムダ軽鎖;ケラトエピセリン;ケラチン;ラクタヘドリン;ラクトフェリン;リゾチーム;肺サーファクタントタンパク質C;メディン;歯原性エナメル芽細胞関連タンパク質;プリオンタンパク質;プロカルシトニン;プロラクチン;セメノゲリンI;血清アミロイドA;スーパーオキシドジスムターゼI;β2−ミクログロブリン;TATAボックス結合タンパク質;タウ;トランスサイレチン;およびα−シヌクレインから選択されるタンパク質を含む、請求項16に記載の方法。
- アルツハイマー病;早期発症型アルツハイマー病;後期発症型アルツハイマー病;発症前アルツハイマー病;ALアミロイドーシス;筋萎縮性側索硬化症(ALS);筋萎縮性側索硬化症/パーキンソニズム認知症複合;嗜銀顆粒性認知症;大動脈中膜アミロイドーシス;ApoAIアミロイドーシス;ApoAIIアミロイドーシス;ApoAIVアミロイドーシス;心房アミロイドーシス;イギリス型/デンマーク型認知症;白内障;大脳皮質基底核変性症;逆まつげに関連する角膜アミロイドーシス;シスタチンCプラーク関連疾患;シスタチンCプラーク関連冠動脈疾患;シスタチンCプラーク関連腎疾患;皮膚苔癬アミロイドーシス;ボクサー認知症;歯状核赤核−淡蒼球ルイ体萎縮症;石灰化を伴うびまん性神経原線維変化病;レヴィー小体認知症;ダウン症候群;家族性アミロイド心筋症(FAC);家族性アミロイドポリニューロパチー(FAP);家族性イギリス型認知症;家族性デンマーク型認知症;家族性脳症;家族性地中海熱;フィブリノゲンアミロイドーシス;フィンランド型遺伝性アミロイドーシス;パーキンソニズムを伴う前頭側頭型認知症;前頭側頭葉変性症(FTLD);前頭側頭葉認知症;ハレルフォルデン‐スパッツ病;血液透析関連性アミロイドーシス;遺伝性脳アミロイド血管症;アミロイドーシスを伴う遺伝性脳出血;遺伝性格子状角膜ジストロフィー;ハンチントン病;アイスランド型遺伝性脳アミロイド血管症;封入体筋炎;注射部位限局性アミロイドーシス;膵島アミロイドポリペプチドアミロイドーシス;リゾチームアミロイドーシス;多発性骨髄腫;筋強直性ジストロフィー;ニーマン・ピック病C型;神経原線維変化を伴う非グアム型運動ニューロン疾患;パーキンソン病;末梢性アミロイドーシス;ピック病;下垂体プロラクチノーマ;脳炎後パーキンソニズム;プリオンタンパク質脳アミロイド血管症;プリオン媒介性疾患;クールー;クロイツフェルト・ヤコブ病(CJD);ゲルストマン・ストロイスラー・シャインカー病(GSS);致死性家族性不眠症(FFI);スクレイピー;海綿状脳症;肺胞タンパク症;進行性皮質下グリオ−シス;進行性核上麻痺;老年性全身性アミロイドーシス;血清AAアミロイドーシス;球脊髄性筋萎縮症;脊髄小脳失調症(SCA1、SCA3、SCA6、またはSCA7);亜急性硬化性全脳炎;全身性アミロイドーシス;家族性アミロイドーシス;野生型アミロイドーシス;神経原線維変化優位型認知症;およびタウオパチーから選択される疾患を処置する方法。
- 前記疾患が、パーキンソン病、アルツハイマー病、およびハンチントン病から選択される、請求項18に記載の方法。
- 前記疾患がアルツハイマー病である、請求項19に記載の方法。
- 前記疾患が、クロイツフェルト・ヤコブ病、クールー、致死性家族性不眠症、およびゲルストマン・ストロイスラー・シャインカー症候群から選択されるプリオン媒介性疾患である、請求項18に記載の方法。
- 請求項1から14のいずれか一項に記載のポリペプチドをコードする核酸を含むオリゴヌクレオチド。
- 前記ポリペプチドをコードする前記核酸が、配列番号37、配列番号38、配列番号39、配列番号40、配列番号41、配列番号42、配列番号43、および配列番号44から選択される配列を含む、請求項22に記載のオリゴヌクレオチド。
- 前記ポリペプチドをコードする前記核酸が、配列番号45、配列番号46、配列番号47、配列番号48、配列番号49、配列番号50、配列番号51、および配列番号52から選択される配列からなる、請求項22に記載のオリゴヌクレオチド。
- 請求項22から24のいずれか一項に記載の核酸を含むベクター。
- 請求項25に記載のベクターを含む宿主細胞。
- 昆虫細胞、真菌細胞、植物細胞、細菌細胞、哺乳動物細胞、およびトランスジェニック動物細胞からなる群から選択される、請求項26に記載の宿主細胞。
- HEK293細胞、HEK293由来細胞、CHO細胞、CHO由来細胞、HeLa細胞、およびCOS細胞からなる群から選択される、請求項27に記載の宿主細胞。
- アミロイドに結合するタンパク質を作製する方法であって、請求項25に記載のベクター中の核酸によってコードされるタンパク質を発現させるステップ、および前記発現されたタンパク質を単離するステップを含む方法。
- 請求項25に記載のベクター中の核酸によってコードされるタンパク質を発現させ、前記発現されたタンパク質を単離することによって産出される、アミロイドに結合するタンパク質。
- 請求項26〜28のいずれか一項に記載の宿主細胞を培養することによって発現される、請求項30に記載のタンパク質。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862685757P | 2018-06-15 | 2018-06-15 | |
US62/685,757 | 2018-06-15 | ||
US201862749499P | 2018-10-23 | 2018-10-23 | |
US62/749,499 | 2018-10-23 | ||
PCT/US2019/037179 WO2019241628A1 (en) | 2018-06-15 | 2019-06-14 | General amyloid interaction motif (gaim) |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021527407A true JP2021527407A (ja) | 2021-10-14 |
JPWO2019241628A5 JPWO2019241628A5 (ja) | 2022-06-01 |
Family
ID=67263052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020569166A Pending JP2021527407A (ja) | 2018-06-15 | 2019-06-14 | 全般的アミロイド相互作用モチーフ(gaim) |
Country Status (14)
Country | Link |
---|---|
US (2) | US11692017B2 (ja) |
EP (1) | EP3806884B1 (ja) |
JP (1) | JP2021527407A (ja) |
CN (1) | CN112672755A (ja) |
AU (1) | AU2019287623A1 (ja) |
BR (1) | BR112020025111A2 (ja) |
CA (1) | CA3102841A1 (ja) |
ES (1) | ES2960493T3 (ja) |
IL (1) | IL279333B2 (ja) |
MX (1) | MX2020013525A (ja) |
PL (1) | PL3806884T3 (ja) |
SG (1) | SG11202012091WA (ja) |
WO (1) | WO2019241628A1 (ja) |
ZA (1) | ZA202100071B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220119468A1 (en) * | 2019-02-22 | 2022-04-21 | Loyola Marymount University | Amyloid peptide variants |
CN117343200B (zh) * | 2023-12-04 | 2024-01-30 | 北京质肽生物医药科技有限公司 | 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082114A1 (en) * | 2011-11-29 | 2013-06-06 | Neurophage Pharmaceuticals, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
WO2014055515A1 (en) * | 2012-10-02 | 2014-04-10 | Neurophage Pharmaceuticals, Inc. | Use of p3 of bacteriophage fusion proteins as amyloid binding agents |
WO2014193935A1 (en) * | 2013-05-28 | 2014-12-04 | Neurophage Pharmaceuticals, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
WO2016090022A1 (en) * | 2014-12-03 | 2016-06-09 | Neurophage Pharmaceuticals, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
-
2019
- 2019-06-14 AU AU2019287623A patent/AU2019287623A1/en active Pending
- 2019-06-14 PL PL19739769.8T patent/PL3806884T3/pl unknown
- 2019-06-14 EP EP19739769.8A patent/EP3806884B1/en active Active
- 2019-06-14 ES ES19739769T patent/ES2960493T3/es active Active
- 2019-06-14 CN CN201980049538.2A patent/CN112672755A/zh active Pending
- 2019-06-14 BR BR112020025111-9A patent/BR112020025111A2/pt unknown
- 2019-06-14 JP JP2020569166A patent/JP2021527407A/ja active Pending
- 2019-06-14 CA CA3102841A patent/CA3102841A1/en active Pending
- 2019-06-14 US US17/251,351 patent/US11692017B2/en active Active
- 2019-06-14 SG SG11202012091WA patent/SG11202012091WA/en unknown
- 2019-06-14 WO PCT/US2019/037179 patent/WO2019241628A1/en active Search and Examination
- 2019-06-14 MX MX2020013525A patent/MX2020013525A/es unknown
-
2020
- 2020-12-09 IL IL279333A patent/IL279333B2/en unknown
-
2021
- 2021-01-05 ZA ZA2021/00071A patent/ZA202100071B/en unknown
-
2023
- 2023-05-19 US US18/320,697 patent/US20230279064A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082114A1 (en) * | 2011-11-29 | 2013-06-06 | Neurophage Pharmaceuticals, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
JP2015505823A (ja) * | 2011-11-29 | 2015-02-26 | ニューロファージ ファーマシューティカルズ, インコーポレイテッド | アミロイド結合剤としてのバクテリオファージのp3の使用 |
WO2014055515A1 (en) * | 2012-10-02 | 2014-04-10 | Neurophage Pharmaceuticals, Inc. | Use of p3 of bacteriophage fusion proteins as amyloid binding agents |
WO2014193935A1 (en) * | 2013-05-28 | 2014-12-04 | Neurophage Pharmaceuticals, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
WO2016090022A1 (en) * | 2014-12-03 | 2016-06-09 | Neurophage Pharmaceuticals, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Non-Patent Citations (1)
Title |
---|
J.MOL.BIOL., vol. 426, JPN6023023911, 2014, pages 2500 - 2519, ISSN: 0005080549 * |
Also Published As
Publication number | Publication date |
---|---|
PL3806884T3 (pl) | 2023-11-20 |
CN112672755A (zh) | 2021-04-16 |
SG11202012091WA (en) | 2021-01-28 |
US20230279064A1 (en) | 2023-09-07 |
ES2960493T3 (es) | 2024-03-05 |
EP3806884C0 (en) | 2023-08-02 |
US20210246179A1 (en) | 2021-08-12 |
EP3806884A1 (en) | 2021-04-21 |
MX2020013525A (es) | 2021-02-26 |
EP3806884B1 (en) | 2023-08-02 |
IL279333A (en) | 2021-01-31 |
IL279333B2 (en) | 2023-06-01 |
ZA202100071B (en) | 2023-04-26 |
WO2019241628A1 (en) | 2019-12-19 |
US11692017B2 (en) | 2023-07-04 |
CA3102841A1 (en) | 2019-12-19 |
BR112020025111A2 (pt) | 2021-04-06 |
AU2019287623A1 (en) | 2021-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10526377B2 (en) | Fusion proteins comprising P3 of bacteriophage | |
US20230279064A1 (en) | General amyloid interaction motif (gaim) | |
JP6440765B2 (ja) | アミロイド結合剤としてのバクテリオファージのp3の使用 | |
US20210015895A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
EA046070B1 (ru) | Общий амилоид-взаимодействующий мотив (gaim) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220524 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240328 |